Tags: Drug.

Amibegron (SR-58611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System and has antidepressant and anxiolytic effects.On July 31 2008 Sanofi-Aventis announced that it has decided to discontinue development of amibegron.

Amibegron.png
ATC prefix
none
CAS number
121524-09-2
FDA UNII code
PDQ3ME68U3
IUPAC name
Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5678-tetrahydronaphthalen-2-yl]oxy)acetate
PubChem
3035442

Loading...

This page contains content from the copyrighted Wikipedia article "Amibegron"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.